What does peptide sequence coverage LC-MS MS analysis actually report?
Sequence coverage is a residue accounting statistic. If the reference sequence contains N amino acids, and accepted identifications together span C of those positions, coverage is C divided by N. Overlapping peptides do not increase the numerator twice. A residue seen only in a spectrum that fails the identification rule is not covered, even if a peak at the expected mass-to-charge ratio was present. Two laboratories cannot compare percentages unless they also compare that rule. Three quantities are often collapsed into one phrase. Sequence coverage counts residues. Peptide coverage counts how many theoretically expected proteolytic peptides were identified. Fragment-ion coverage, used when an intact or middle-down precursor is fragmented, counts residues supported by product ions from that precursor. A tryptic map can show high sequence coverage while each peptide is identified from only a few b- or y-ions. High coverage is a platform outcome. Wu and colleagues described extended range proteomic analysis as a sensitive LC-MS approach aimed at high sequence coverage of complex, extensively modified proteins, illustrated with beta-casein and the epidermal growth factor receptor (PMID:16083266). Biringer and colleagues reported enhanced sequence coverage of proteins in human cerebrospinal fluid using multiple enzymatic digestion and linear ion trap LC-MS/MS (PMID:16772279). The accounting principle transfers: coverage rises when complementary cleavages place silent residues into peptides the column retains and the mass spectrometer fragments. For a short synthetic peptide the arithmetic can still mislead. A 15-residue chain identified as one intact precursor, with product ions supporting both termini and the internal sequence, can be reported as fully covered without a protease. A longer chain can match the intact mass and still leave a central stretch unsupported. The batch record should state which experiment was performed.
Which identification rules change a reported coverage percentage?
A reproducible coverage figure depends on inputs that belong in the analytical record. The reference sequence should be in one-letter code, including any intended non-proteinogenic residue, N-terminal modification or C-terminal amide, and excluding counter-ions. The cleavage model should state the protease or the decision to use none, the missed-cleavage allowance, and whether limited proteolysis was used. Method identity should name the mass analyser, fragmentation mode and acquisition type. The identification threshold should state mass tolerance, minimum peptide length, minimum matched product ions, and any score or false-discovery cut-off. A position counts once if at least one accepted peptide contains it. A missed-cleavage peptide that overlaps two fully cleaved peptides does not raise coverage, but it can rescue a residue that otherwise existed only in a dipeptide the software never identified. Chemical isotope labelling liquid chromatography-Orbitrap mass spectrometry was developed for comprehensive analysis of dipeptides (PMID:37039432). If software discards peptides below a set length, those residues stay uncovered even when the ions were acquired. Modifications need their own column. An oxidised methionine can still count as covered, while the oxidation remains a separate related-substance observation. Site localisation is stricter than residue coverage: a modification may sit on a peptide and still not be placed on one residue if the product-ion series is incomplete. Online LC-FAIMS-MS/MS has been described for the analysis of phosphorylation in proteins, placing a gas-phase separation before tandem MS of modified peptides (PMID:26584930). Targeted bottom-up characterisation of recombinant monoclonal antibodies by multidimensional LC/MS shows how a mapping experiment is specified for a defined protein rather than a proteome digest (PMID:32901474). High-resolution ion-mobility-enabled peptide mapping has been used to monitor critical quality attributes as a controlled measurement (PMID:33835810). Changing the mass window, the enzyme or the minimum length changes the percentage without any change in the vial.
Why do reversed-phase maps miss hydrophilic and early-eluting peptides?
Conventional reversed-phase peptide mapping assumes that informative peptides are retained, eluted across a solvent gradient, and ionised by electrospray. Very hydrophilic sequences can travel with the solvent front, poorly resolved from salts, and can be excluded by the acquisition window. If those residues are never identified, sequence coverage falls even though the vial contains the expected chain. The gap is then chromatographic, not automatic evidence of a deletion. Total retention liquid chromatography-mass spectrometry was reported as a means to achieve maximum protein sequence coverage (PMID:33724001). Before a low coverage figure is treated as a sequence defect, the record should show whether early-eluting material was acquired, whether the gradient began highly aqueous, and whether a second separation was used for the polar fraction. A blank, a solvent-front window, and the first and last minutes sent to the mass spectrometer belong in that review. Sample preparation can open the same gap. Filter-assisted protein precipitation has been described as a pre-treatment for LC-MS peptide mapping in biosimilar characterisation (PMID:37364451). Precipitation, filtration and desalting are selective. Peptides that do not bind the filter, or that precipitate incompletely, never reach the column, so a map generated after aggressive clean-up can under-represent terminal or hydrophilic regions. For a lyophilised synthetic peptide in a simple diluent, direct dissolution, a defined dilution and a documented load amount are often the clearer experiment, with the main-species response checked by an orthogonal ultraviolet chromatogram. An impulse-driven heated-droplet deposition interface has been described for capillary and microbore LC-MALDI MS and MS/MS, placing fractions on a target for later tandem analysis (PMID:17605467). It lets a laboratory revisit a fraction and avoid the duty-cycle limit of one online data-dependent run. When coverage is compared across laboratories, the record should state whether acquisition was online electrospray, ion-mobility-assisted electrospray, or an offline MALDI map.
How do middle-down and top-down experiments redefine coverage?
Bottom-up coverage is built from many short peptides. Middle-down coverage is built from fewer, longer polypeptides produced by limited proteolysis or restricted chemical cleavage. A coordinated middle-down workflow for these longer polypeptides has been described (PMID:28233997). Peptide length, chromatographic peak capacity and fragmentation efficiency interact, so the resulting percentage is method-specific. Longer polypeptides can cover a contiguous stretch that a tryptic map splits into a retained peptide and a lost dipeptide. A middle-down percentage is not numerically comparable with a tryptic percentage for the same reference sequence. Gas-phase separation is often paired with these larger ions because the spectra are dense. A GeLC-FAIMS-MS workflow has been reported for in-depth middle-down proteomics, combining gel-based fractionation with differential ion mobility before mass analysis (PMID:37548120). Field asymmetric ion mobility does not create sequence information. It reduces chimeric spectra so fragment ions can be assigned to one precursor. If two polypeptides co-elute and co-fragment, an uncritical search can invent coverage or reject a true peptide. A narrow isolation window and a stated chimeric-spectrum rule are further controls. Top-down experiments remove the protease. Coverage is then the fraction of the intact sequence supported by product ions from the intact precursor or from a small set of charge states. A methods description of top-down proteomics applied to human cerebrospinal fluid sets out that intact-protein logic for a complex biofluid (PMID:31432414). For a research peptide of known intended mass, direct MS/MS of the intact synthetic chain is often the more relevant experiment: it tests the precursor mass and whether product ions order the residues. Fragmentation, not digestion, limits that result. Electron-based and collision-based methods favour different cleavage sites, so one rich ion series can still leave a gap. The batch report should name the fragmentation mode, the charge states inspected, and the ion series required before a residue is marked supported. Without those fields, a top-down value cannot be reproduced, and it cannot be reconciled with a bottom-up map of the same lot.
How should an Australian laboratory document coverage on a research lot?
A coverage statement is useful only when it traces to one lot, one reference sequence and one raw data file. The block should name the material and lot identifier, repeat the reference sequence or a controlled sequence identifier, state the intact monoisotopic mass and observed mass error, and then state the coverage experiment. Intact MS/MS entries should list charge states, fragmentation mode and the ion series used. Digest entries should list the protease, missed-cleavage setting, gradient family and identification thresholds. The percentage comes last, not first. Gaps should be listed as residue intervals. An unsupported N-terminal stretch is not the same finding as a poorly fragmenting central residue, and neither is the same as a truncation-related substance seen as an earlier ultraviolet peak and a separate mass. Coverage does not rank those possibilities. A reversed-phase chromatogram at a peptide-bond wavelength, a related-substance table and the tandem map should be read together. A single main ultraviolet peak, an intact mass match and terminus-supporting product ions form a coherent identity package for many short research peptides. High digest coverage with an unexplained early ultraviolet peak is incomplete if the search considered only the full-length sequence. Australian procurement comparisons should use that reading order. Confirm that the coverage value was measured on the supplied lot rather than copied from a historical method sheet. Confirm whether the search database contained only the intended sequence or also common deletions, insertions and incomplete deprotection products. A search against the intended sequence alone cannot identify a wrong sequence that still shares some fragment ions. Sequence coverage remains an analytical identity statistic. It sits beside area-normalised purity, net peptide content, counter-ion identity and water content as separate lines. It is not a statement of biological effect, and it does not authorise any use outside research.
Frequently asked questions
Is 100 percent sequence coverage required for a research peptide lot?
No universal percentage is set by the analytical literature cited here, and a research-lot certificate should not borrow an antibody release number without a validation record. Full coverage means every residue was supported at least once under a stated rule. A lower figure can reflect a lost hydrophilic peptide, a short peptide discarded by software, or a real sequence gap. The auditable requirement is a declared method, a declared threshold and a listed unsupported interval, not an unexplained percentage.
Does peptide sequence coverage equal chromatographic purity?
No. Sequence coverage counts residues supported by accepted tandem spectra. Chromatographic purity is an area-normalised detector result for peaks in a stated run. A lot can be highly pure by area and still show incomplete coverage if polar peptides were not retained. It can also show high coverage while a minor related substance remains visible in the chromatogram, if that minor species was not the sequence used in the search. The two results answer different questions and should be reported on separate lines.
Why do two laboratories report different coverage for the same lot?
Coverage is the output of a rule, not a property stamped on the vial. Different proteases, missed-cleavage settings, minimum peptide lengths, mass tolerances and false-discovery cut-offs admit different spectra. One laboratory may acquire the solvent front and another may divert it. One may use ion mobility or an offline MALDI map and another a single online electrospray run. Unless both reports state the reference sequence, the experiment type and the identification threshold, the percentages are not comparable.
Should every research peptide be digested before coverage is calculated?
Not always. Short synthetic peptides are often better examined as intact precursors, with coverage taken from product ions of the intact mass. Digestion is more informative when the chain is long, when a modification must be placed in a smaller peptide, or when an orthogonal map is required beside intact mass. A digest percentage and an intact MS/MS percentage describe different experiments. The certificate should say which one was performed rather than implying that both were.
What should a coverage line on a certificate of analysis include?
At a minimum, include the lot identifier, the reference sequence or sequence identifier, the experiment type, the protease or fragmentation mode, the identification thresholds, the coverage percentage and any unsupported residue intervals. Intact mass and mass error should sit beside that line so a reader can see whether the precursor matched before fragments were interpreted. A percentage alone, without method identity and without the file reference used by the laboratory, cannot be audited later.
Does gas-phase separation increase sequence coverage by itself?
Field asymmetric ion mobility and high-resolution ion mobility separate ions before mass analysis. They can reduce chimeric spectra and reveal peptides that were masked, which may allow additional identifications under the same threshold. They do not add residues to the numerator unless those residues are then identified. A report that cites FAIMS or ion mobility should still state the identification rule. Mobility is a separation dimension, not a substitute for sequence evidence.
References
- PMID:16083266 — Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications-comprehensive analysis of beta-casein and epidermal growth factor receptor (EGFR) — J Proteome Res — 2005
- PMID:16772279 — Enhanced sequence coverage of proteins in human cerebrospinal fluid using multiple enzymatic digestion and linear ion trap LC-MS/MS — Brief Funct Genomic Proteomic — 2006
- PMID:17605467 — Impulse-driven heated-droplet deposition interface for capillary and microbore LC-MALDI MS and MS/MS — Anal Chem — 2007
- PMID:26584930 — Online LC-FAIMS-MS/MS for the Analysis of Phosphorylation in Proteins — Methods Mol Biol — 2016
- PMID:28233997 — Toward an Optimized Workflow for Middle-Down Proteomics — Anal Chem — 2017
- PMID:31432414 — Top-Down Proteomics Applied to Human Cerebrospinal Fluid — Methods Mol Biol — 2019
- PMID:32901474 — Targeted Bottom-up Characterization of Recombinant Monoclonal Antibodies by Multidimensional LC/MS — Anal Chem — 2020
- PMID:33724001 — Total Retention Liquid Chromatography-Mass Spectrometry to Achieve Maximum Protein Sequence Coverage — Anal Chem — 2021
- PMID:33835810 — High-Resolution Ion-Mobility-Enabled Peptide Mapping for High-Throughput Critical Quality Attribute Monitoring — J Am Soc Mass Spectrom — 2021
- PMID:37039432 — Development of Chemical Isotope Labeling Liquid Chromatography Orbitrap Mass Spectrometry for Comprehensive Analysis of Dipeptides — Anal Chem — 2023
- PMID:37364451 — A novel filter-assisted protein precipitation (FAPP) based sample pre-treatment method for LC-MS peptide mapping for biosimilar characterization — J Pharm Biomed Anal — 2023
- PMID:37548120 — GeLC-FAIMS-MS workflow for in-depth middle-down proteomics — Proteomics — 2024
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
